60 Degrees Pharmaceuticals, Inc. filed a Current Report on Form 8-K on September 8, 2026, to furnish an updated investor presentation. The document, included as Exhibit 99.1, details the company's strategy for leveraging its marketed antimalarial platform, ARAKODA (tafenoquine), for potential indication expansion into vector-borne diseases, specifically babesiosis.
The company’s core investment thesis centers on the label expansion of ARAKODA. The presentation outlines a staged path to treat babesiosis, a parasitic red-blood-cell infection with an estimated 25,000 annual medical insurance claims in the U.S. The company notes that while standard of care treatments for babesiosis have a cure rate of approximately 30% in refractory patients, there are no FDA-approved treatments specifically for this indication.
Regarding the commercial base, ARAKODA is currently marketed for malaria prophylaxis in adults. The company highlights a non-clinical proof-of-concept package, including blood-smear phenotype data and SCID-mouse combination studies, to support the repositioning rationale. The presentation indicates that the company is preparing a dossier for a meeting with the FDA regarding the treatment of human babesiosis.
Financial data included in the snapshot shows Q2 2026 net product revenue of $208,000, a 106% year-over-year increase, with a gross profit of $57,000 and a gross margin of approximately 27%. The company reported cash and equivalents of $1.0 million as of June 30, 2026, and estimated an operating cash use of $5.0 million for the six months ended June 30. The company also disclosed that it completed a private placement on July 31, 2026, raising approximately $1.0 million gross at a price of $1.74 per share.
The presentation outlines a milestone path for the babesiosis program, including an interim analysis scheduled for October 6, 2026, and a potential submission of a supplemental New Drug Application (sNDA). The company also lists several other planned development opportunities, including a veterinary indication for tafenoquine and potential treatments for post-treatment Lyme disease syndrome and Alpha-Gal syndrome.
